BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

Dyne’s myotonic dystrophy antisense therapy reduces gene expressionDyne Therapeutics Inc. (NASDAQ:DYN) reported data from a new mouse model of severe disease showing its myotonic dystrophy type 1 (DM1) antisense oligonucleotide therapy reduced nuclear DMPK RNA levels...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Inhibiting BMI1 and BCL-2 to treat diffuse intrinsic pontine glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Inhibiting epigenetic regulator BMI1 alone or in combination with BCL-2 inhibition could treat diffuse intrinsic pontine glioma (DIPG), an aggressive childhood brain cancer. A screen in two human DIPG...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

The move toward sickle cell disease therapies that address the pathology’s root causes is reflected in promising early-stage readouts at ASH, which include both disease event rates and changes in red blood cell biology. The...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc. entered into a collaboration agreement with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to identify drug candidates...
BioCentury | Aug 18, 2020
Product Development

Unity outlines path forward for anti-aging programs after Phase II osteoarthritis failure

After the failure of its lead anti-aging program in osteoarthritis, Unity believes more objective clinical endpoints and robust preclinical data for its next-in-line ophthalmology candidate mean that program won’t suffer the same fate in the...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

By enriching its coffers with a further $2.1 billion from existing shareholders, BeiGene gains a formidable cash position as it brings to market a handful of products in the U.S. and China and advances a...
BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

Venclexta combo shows survival benefit in AML Partners Roche (SIX:ROG; OTCQX:RHHBY) and AbbVie Inc. (NYSE:ABBV) said Venclexta venetoclax plus azacitidine significantly improved overall survival and composite complete remission rate among acute myelogenous leukemia (AML) patients...
BioCentury | Mar 3, 2020
Product Development

March 2 Quick Takes: FDA Priority Review for MorphoSys-Incyte lymphoma therapy; plus Pfizer-Lilly, Merck, AbbVie, Novartis, Cerovene

Priority Review for MorphoSys follows Incyte deal FDA accepted and granted Priority Review to a BLA for tafasitamab from MorphoSys AG (NASDAQ:MOR; Xetra:MOR) to treat relapsed or refractory diffuse large B cell lymphoma in combination...
Items per page:
1 - 10 of 714